Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 6:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 27,752 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo and sham treatment Clear all
Completed Phase 2 Interventional Results available

Cockroach Immunotherapy in Children and Adolescents

NCT03541187
View directory record Official record
Conditions
Persistent Asthma
Interventions
German cockroach allergenic extract, Placebo for German cockroach allergenic extract
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 17 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
11
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Oct 15, 2026, 6:08 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Isradipine Enhancement of Virtual Reality Cue Exposure for Smoking Cessation

NCT03083353
View directory record Official record
Conditions
Nicotine Dependence, Smoking, Cigarette, Smoking Cessation, Smoking Behaviors, Smoking Reduction, Craving
Interventions
Isradipine, Cue Exposure
Drug · Behavioral
Lead sponsor
Jasper A. Smits
Other
Eligibility
18 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 15, 2026, 6:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment

NCT01561937
View directory record Official record
Conditions
Haemostasis, Healthy
Interventions
warfarin, eptacog alfa (activated), placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older · Male only
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2016 · Synced Oct 15, 2026, 6:08 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Safety and Acceptability of Tenofovir 1% Gel in Adolescent Females

NCT02245945
View directory record Official record
Conditions
HIV Prevention
Interventions
TFV 1% vaginal gel, HEC Placebo Gel
Drug
Lead sponsor
CONRAD
Other
Eligibility
15 Years to 17 Years · Female only
Healthy volunteers
Accepts healthy volunteers
U.S. locations
2
States / cities
The Bronx, New York • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Oct 15, 2026, 6:08 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

CYP3A4 Activity and Mineral Homeostasis

NCT02019875
View directory record Official record
Conditions
Vitamin D and Calcium Homeostasis
Interventions
Rifampin, Clarithromycin, Grapefruit Juice, Placebo
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 60 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Oct 15, 2026, 6:08 AM EDT
Not listed Phase 4 Interventional

The Effect of Dexamethasone on the Duration and Functionality of Bupivacaine Intercostal Nerve Blockade

NCT02005575
View directory record Official record
Conditions
Post Minimally Invasive Thorascopic Surgical Pain
Interventions
Bupivacaine and Dexamethasone, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2015 · Synced Oct 15, 2026, 6:08 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

High Fat Diet: Oxidative and Cardiovascular Effects

NCT00696228
View directory record Official record
Conditions
Obesity
Interventions
Placebo, MUFA, PUFA, SFA
Dietary Supplement
Lead sponsor
Vanderbilt University
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 10, 2020 · Synced Oct 15, 2026, 6:08 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Diabetic Cardiomyopathy and Heart Failure

NCT05571865
View directory record Official record
Conditions
Diabetic Cardiomyopathies, Heart Failure
Interventions
Probiotic
Dietary Supplement
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 15, 2026, 6:08 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Saxenda: Underlying Mechanisms and Clinical Outcomes

NCT02944500
View directory record Official record
Conditions
Obesity
Interventions
liraglutide, Placebo
Drug · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 15, 2026, 6:08 AM EDT
Not listed Phase 1Phase 2 Interventional

Intranasal Neuropeptide Y in Clinical Trial in Level Two Trauma Patients for PTSD and Acute Stress Disorder

NCT04071600
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic, Stress Disorders, Traumatic, Acute
Interventions
Neuropeptide Y, Placebo
Drug · Other
Lead sponsor
New York Medical College
Other
Eligibility
18 Years to 65 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 15, 2026, 6:08 AM EDT
Completed Phase 3 Interventional Results available

Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer

NCT01361607
View directory record Official record
Conditions
Pain, Advanced Cancer
Interventions
Nabiximols, Placebo (GA-0034)
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
20
States / cities
Glendale, California • Santa Rosa, California • Clearwater, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 15, 2026, 6:08 AM EDT
Completed Phase 4 Interventional

Study of Bronchodilation Effects of Cetirizine

NCT01781507
View directory record Official record
Conditions
Allergic Rhinitis, Asthma
Interventions
Cetirizine, Placebo
Drug
Lead sponsor
California Allergy and Asthma Medical Group, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Oct 15, 2026, 6:08 AM EDT
Active, not recruiting Phase 3 Interventional

An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps

NCT07424144
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
Itepekimab (SAR440340), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
La Mesa, California • Oklahoma City, Oklahoma • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 15, 2026, 6:08 AM EDT
Terminated Not applicable Interventional Results available

Napping, Sleep, Cognitive Decline and Risk of Alzheimer's Disease

NCT03256539
View directory record Official record
Conditions
Sleep, Alzheimer Disease, Cognitive Impairment, Aging, CBT
Interventions
Sleep intervention, Placebo intervention
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
65 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 15, 2026, 6:08 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

NCT02446912
View directory record Official record
Conditions
Active Systemic Lupus Erythematosus
Interventions
Anifrolumab, Placebo
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
52
States / cities
Birmingham, Alabama • El Cajon, California • La Jolla, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Oct 15, 2026, 6:08 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Autonomic and Renal Contributions to Hypertension With ADT

NCT07848828
View directory record Official record
Conditions
Androgen Deprivation Therapy, Prostate Cancer, Hypertension, Autonomic Dysfunction, Renal Disease
Interventions
Gonadotropin Releasing Hormone Agonists (GNRH), Androgen receptor (AR) inhibitor, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
40 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 15, 2026, 6:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Staccato Loxapine Single Dose PK

NCT00444028
View directory record Official record
Conditions
Schizophrenia
Interventions
inhaled Loxapine 0.625 mg, inhaled Loxapine 1.25 mg, inhaled Loxapine 2.5 mg, inhaled Loxapine 5 mg, inhaled Loxapine 10 mg, inhaled Placebo (0 mg)
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Oct 15, 2026, 6:08 AM EDT
Active, not recruiting Phase 3 Interventional

IBP-9414 for the Prevention of Necrotizing Enterocolitis - The Connection Study

NCT03978000
View directory record Official record
Conditions
Necrotizing Enterocolitis
Interventions
IBP-9414, Placebo
Drug
Lead sponsor
Infant Bacterial Therapeutics
Industry
Eligibility
Up to 48 Hours
Enrollment
2,158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
54
States / cities
Tucson, Arizona • Little Rock, Arkansas • Loma Linda, California + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2024 · Synced Oct 15, 2026, 6:08 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Efficacy of Quetiapine for Pediatric Delirium

NCT02056171
View directory record Official record
Conditions
Delirium
Interventions
quetiapine, Placebo
Drug · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
1 Year to 22 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 15, 2026, 6:08 AM EDT
Completed Phase 3 Interventional

A Multicenter Randomized Placebo-Controlled Double-Blind Study to Assess Efficacy and Safety of Glutamine and Creatine Monohydrate in Duchenne Muscular Dystrophy (DMD)

NCT00018109
View directory record Official record
Conditions
Muscular Dystrophy, Duchenne
Interventions
glutamine, creatine monohydrate
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
5 Years to 10 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 15, 2026, 6:08 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Efficacy Study to Evaluate Antimicrobial Effectiveness of ZuraPrep™

NCT02221232
View directory record Official record
Conditions
Surgical Site Infection
Interventions
Chloraprep, ZuraPrep, ZuraPrep Vehicle
Drug
Lead sponsor
Zurex Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Oct 15, 2026, 6:08 AM EDT
Completed Not applicable Interventional Results available

Effect of Oxytocin on Craving and Therapy Response

NCT01827332
View directory record Official record
Conditions
Marijuana Dependence
Interventions
Oxytocin, Saline
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 2, 2017 · Synced Oct 15, 2026, 6:08 AM EDT
Recruiting Phase 3 Interventional

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

NCT07743463
View directory record Official record
Conditions
Obesity, Overweight, Chronic Weight Management
Interventions
ASC30 tablets A1, Placebo
Drug
Lead sponsor
Ascletis Pharma (China) Co., Limited
Industry
Eligibility
18 Years and older
Enrollment
3,003 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
69
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 15, 2026, 6:08 AM EDT
Completed Phase 1 Interventional

A Study of the Effect of INCB013739 on Cortisone Reducing Enzyme Activity in Obese People Predisposed to Diabetes

NCT00398619
View directory record Official record
Conditions
Insulin Resistance, Obesity
Interventions
INCB13739
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Beverly Hills, California • Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2012 · Synced Oct 15, 2026, 6:08 AM EDT